MYBIOPASSPORT
Mybiopassport.com, the platform set-up by CoreMedica Europe, a Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of their “Nutritional Profile” and “Sport Performance Profile” tests, which will complement their current “Immunity Profile” and “COVID-19” tests
Mybiopassport proposes at-home blood collection tests to help anyone become the “heroes of their own health” . Individuals can now collect only a few drops of blood at their homes and send their samples by regular prepaid mail to the company’s authorized laboratory located in Geneva, Switzerland, to determine the levels of key biomarkers known to support sport performance, a healthy nutrition, and the immune system. The tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal through a simple sign-up procedure.
The purposes of these tests are as follows :
- Nutritional – A tool informing the client of their current nutritional status based on past habits and providing personalized recommendations on how to correct any deficiencies or excesses through nutrition. The first of its kind, this test provides information about the levels of micronutrients belonging to all four classes of essential micronutrients, namely vitamins, minerals, fatty acids and amino acids. These are all linked to specific bodily functions (fatigue, sleep, anxiety, etc.) making this test the most comprehensive and informative on the market.
- Sport Performance – A tool developed to help amateur and professional athletes determine if their performance related biomarkers are at their optimal levels to allow them to perform at their best. All the biomarkers tested are linked to specific sport related functions, such as recovery , muscle growth, energy delivery, or even as specific as exercise induced joint pain.
- Immunity - The COVID-19 & Immunity Profile, powered by Mybiopassport, lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies. More importantly, the Immunity Profile test also delivers actionable nutritional recommendations based on a set of key biomarkers known to support the immune system, including vitamin D, zinc and magnesium.
It is now widely accepted that the first step towards a healthy body is good nutrition. Indeed, multiple studies have shown that the risks of developing cardiovascular disease, diabetes, and even dementia are strongly linked to long-term nutritional habits. Recent scientific reports and publications have highlighted the role of nutrition, optimal micronutrient status and a well-functioning immune system as a modifiable factor in reducing the risk of viral infections and their severity. These publications highlight the key role of a good nutritional status for a well-functioning immune system.
Mybiopassport’s mission is clearly to democratize access to specific health-related information and to give people the means to not only understand, but also act on their health through nutrition and lifestyle. They firmly believe in individual empowerment and that the access to personalized health information is the first step towards preventing potential health issues.
Mybiopassport relies on a unique technology in the personalized analysis of biological data on three main axes:
- Pre-analytical with the easy collection of a few drops of blood anywhere, at any time and by anyone,
- Analytical, with the measurement of an unprecedentedly large number of phenotypic biomarkers, via a unique know-how developed over several years,
- Post-analytical, providing not only a scientific result, but personalized recommendations based on a patented technology applied in several fields, such as immunity, nutrition, sport, longevity and anti-aging.
Individuals can now collect a few drops of blood from the comfort and safety of their homes and send their samples by prepaid regular mail to Mybiopassport’s laboratory in Geneva.
The Nutritional, Sport Performance and Immunity tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal with test results reviewed by health professionals.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a person’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018 and its recent acquisition by Swiss Medical Group Holding Luxembourg SA, CoreMedica Europe expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
Civil Air Patrol Expands Fleet With 15 New Cessna Aircraft to Support Lifesaving and Community Missions15.12.2025 17:00:00 CET | Press release
Latest deliveries bring CAP’s Cessna fleet to more than 500 aircraft nationwide Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced today that Civil Air Patrol (CAP), the world’s largest operator of Cessna aircraft, is strengthening its national mission capabilities with an order for 15 additional piston-engine aircraft, including seven Cessna Skyhawk 172 and eight Cessna Skylane 182 models scheduled for delivery throughout 2026. The order follows recent deliveries of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft, expanding CAP’s fleet to more than 500 Cessna aircraft nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215613573/en/ Delivery of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft joins CAP’s fleet of more than 500 Cessna aircraft nationwide. Cessna aircraft are designed and produced by Textron Aviation. “Civil Air Patrol’s miss
Winston & Strawn and Taylor Wessing UK to Combine, Creating a Premier Transatlantic Law Firm15.12.2025 16:52:00 CET | Press release
Winston Taylor to build on shared vision and culture in establishing a transatlantic powerhouse for major litigation, critical transactions, strategic IP, and private wealth Winston & Strawn and Taylor Wessing’s UK-led business announced today their intention to combine, creating a premier transatlantic law firm that would operate under a new shared name, Winston Taylor. The combination responds to increasing client demand for seamlessly integrated US–UK–EU counsel for the businesses, people, and markets driving capital and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215914957/en/ The combination once final will unite two international firms with more than 400 years of combined history, complementary strengths, and a common vision to meet clients’ evolving global needs. The combined firm will include more than 1,400 lawyers, establishing one of the largest transatlantic firms whose footprint is primarily in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom